Latest news
Alzheimer’s Pill Has Finished the Trial. Evidence Has Not.
AriBio’s POLARIS-AD Phase III trial of AR1001 has completed its 52-week treatment phase. The safety update is useful, but the result that matters is still coming.
IPM Brief – The Shortcut Is Not the Pathway
Liver Cancer Is Moving Beyond TACE Alone
ctDNA Is Becoming the New Argument Over Chemotherapy
Microglia Are Not a Shortcut to Alzheimer’s Certainty
India Approved Its First Dengue Vaccine. Access Is Still Unwritten.
Plastic in the coronary bloodstream: micro- and nanoplastics raise a new cardiovascular warning
The baby sets the schedule. Postpartum diet advice still pretends mothers control the clock
The Most Powerful Oncology Tool This Week Was a Check-In
Myeloma Patients May Not Need Treatment Forever
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.